New government rules aimed at curbing overseas deals that cut corporate taxes appear to be working, just not entirely the way regulators intended.
Salix Pharmaceuticals Ltd., based in Raleigh, N.C., said Friday it will scrap a planned merger with the subsidiary of an Italian drugmaker due to a changed “political environment” that creates uncertainty about the deal’s benefits.
Recommended Stories
Print subscriber? Click here to login/register your account
Digital subscriber? Click here to login/register your account.